Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 10/20 | 0.58 |
| ▸ | PYGM | P11217 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TK1 | P04183 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071202 | 1.00 | TK2 (0.58) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL3071205 | 1.00 | TK2 (0.58) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL2922428 | 1.00 | TK2 (0.58) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL2922432 | 1.00 | TK2 (0.58) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL18573991 | 0.91 | TK2 (0.70) | TK2PYGM | |
| SCHEMBL6888284 | 0.91 | TK2 (0.70) | TK2PYGM | |
| SCHEMBL14916547 | 0.91 | TK2 (0.70) | TK2PYGM | |
| SCHEMBL14946349 | 0.91 | TK2 (0.70) | TK2PYGM | |
| SCHEMBL14929316 | 0.91 | TK2 (0.70) | TK2PYGM | |
| SCHEMBL6888282 | 0.91 | TK2 (0.70) | TK2PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492537-B2 | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy | RESPROTECT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotech GmbH (DE) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | TYMP, ENTPD5, NTPCR | TK2 34/4885PYGM 1888/4885CYP1A2 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.